AIMT stock forecast
Our latest prediction for Aimmune Therapeutics, Inc.'s stock price was made on the March 12, 2020 when the stock price was at 14.56$.
In the short term (2weeks), AIMT's stock price should outperform the market by 1.15%. During that period the price should oscillate between -11.14% and +21.74%.
In the medium term (3months), AIMT's stock price should outperform the market by 0.66%. During that period the price should oscillate between -37.80% and +41.18%.Get email alerts
Create a solid portfolio with AIMT
About Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.97$ per share.
The book value per share is 4.92$
Three months stock forecastMarch 12, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|